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What is an Organoid?

Specific Aim

• An organoid is a three-dimensional model of an organ. Liver organoids can be
made from induced pluripotent stem cells7

• Find an effective model for treating liver cancer at all stages of growth by using

• These organ-like models have been used in the clinical setting for a few years
Before organoids were created, two-dimensional in vitro cells and mouse models
were the common modes of modeling cancer metastasis6

• Tumor organoids will be introduced to different treatments at varying dosages in

• Different types of organoids

• Hypothesis: Liver tumor organoids will be effective models for testing

tumor organoids
order to measure the changes in tumor growth

(Fig. 1, Fig. 2, and Fig. 3)

chemotherapy and immunotherapy drug effectiveness in treating liver cancer.

Figure 1: immunofluorescent
image of a brain organoid.8

Figure 2: image of an
intestinal organoid.8

Potential Pitfalls

Figure 3: image of a
heart organoid.3

• Organoids are still relatively new concept in organ modeling
• Expenses can add up when growing and maintaining organ models

Prevalence and Treatments

• Human models will require strict protocol for maintaining the organ-tike tissue

• Liver cancer is the fifth most common cancer found in men and the ninth most

• Potential ethical problems associated with the use of human tissues in the lab

common found in women4

Potential Conclusions

• In 2018 there were more than 840,000 new cases5
• Around 4% of people that are diagnosed with stage four liver cancer have a fiveyear survival rate5

1. The liver tumor organoids grown directly from patient tumors will be the more
effective model for testing immunotherapy and chemotherapy drugs (Part A in

• Common causes

Figure 4).

o Diabetes2

2. The healthy liver cells induced into cancerous cells could be a model for learning

o Cirrhosis2

how cancer effects an individual and how an individual will respond to various

• Chemotherapy treatments include cisplatin, doxorubicin, and oxaliplatin1

treatments (Part B in Figure 4).

• Immunotherapy treatments include pembrolizumab (Keytruda) and nivolumab

3. Neither cultured liver organoids will be a good model for understanding the

• With both types of treatment the 5-year relative survival rates are low1

mechanism of liver cancer, or how immunotherapy and chemotherapy drugs

o Localized cancer 31%

affect liver tissue in the human body

o Regional 11%

For liver tumor organoids to fit my hypothesis:

o Distant 2%

o Tumor regression would be seen in effective drug environments
o No onset of tumor growth seen in a treated, cultured organoid

Methods
•Patient liver tumor cells will be directly suspended in
Matrigel. Growth factors will be added to the tumor cells,
allowing them to mature in a 3-D shape (Fig. 4, part A)
o
o

Chemotherapy drugs at several different concentrations will be
introduced
Immunotherapy drugs at several different concentrations will be
introduced

•Healthy liver tissue will be added to the Matrigel. Gene
editing will transform them into tumor organoids (Fig. 4,
part B)
o
o
Figure 4: Methods of culturing liver cancer organoids9
A:Liver cancer cells are directly removed from a biopsied tumor sample.
B: Normal liver tissue organoids are being transformed into cancerous organoids by using gene editing.
C: Using liver organoids to observe liver cancer mechanisms and how liver cancer cells react to three different drugs.

Chemotherapy drugs at several different concentrations will
be introduced
Immunotherapy drugs at several different concentrations will
be introduced

• Comparison of tumor differences between the
different treatments and different growth protocols
(Fig. 4, part C and Fig. 5)

Grow liver tumor organoids using standard
protocol (figure 4)
Organoids introduced to cisplatin,
doxorubicin, and oxaliplatin chemotherapy
drugs
Organoids introduced to pembrolizumab and
nivolumab
Size differences of the control and tumor
organoids will be compared
Drugs will be ranked based on the growth
results obtained in the study
Figure 5: Methodology for this proposal.
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